Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 03, 2015 7:24 AM ET

Diversified Consumer Services

Company Overview of Johns Hopkins University

Company Overview

Johns Hopkins University is an educational institution offering undergraduate, graduate, part-time, summer, and distance education programs. The school of the university includes Krieger School of Arts and Sciences, Whiting School of Engineering, School of Professional Studies in Business and Education, School of Medicine, School of Nursing, Bloomberg School of Public Health, Nitze School of Advanced International Studies, The Peabody Institute, and Applied Physics Laboratory. Johns Hopkins University was established in 1876 and is based in Baltimore, Maryland. The university has endowment assets worth $2608.5 millions.

3400 North Charles Street

Baltimore, MD 21218-2683

United States

Founded in 1876

Phone:

410-516-8171

Fax:

410-516-6025

Key Executives for Johns Hopkins University

President
Age: 54
Senior Associate Dean for Finance & Administration and Senior Associate Dean for Krieger School of Arts & Sciences
Age: 59
Executive Director of Communications and Public Affairs
Vice President of Communications and Public Affairs
Compensation as of Fiscal Year 2014.

Johns Hopkins University Key Developments

MaxCyte Inc. and Johns Hopkins University Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-Cell Therapies

MaxCyte Inc. announced a strategic research collaboration with Johns Hopkins University (JHU) to develop unique Chimeric Antigen Receptor (CAR) T-cell therapies, which harness patients own immune systems to combat cancers. MaxCyte's unique approach to CAR cell therapy allows targeting of solid tumor cancers by enabling control over the on-target, off-tumor toxicity, which limits other CAR therapies to hematological cancers. MaxCyte achieves this by introducing the CAR construct as a transiently expressing messenger RNA (mRNA), thus allowing control of the duration of expression and toxicity against target antigens in normal tissue. This unique approach also avoids the cell expansion step required for standard approaches, dramatically reducing manufacturing time and expense for CAR therapies from days or weeks to a matter of hours. The preclinical work performed in collaboration with JHU will support a future planned Investigational New Drug (IND) filing for a CAR therapy targeting a broad range of solid tumors. No financial terms are disclosed.

Good Start Genetics, Inc. Enters Exclusive License Agreement with Johns Hopkins University for Noninvasive Prenatal Testing

Good Start Genetics Inc. announced that it has expanded its exclusive relationship with Johns Hopkins University (JHU) for FAST-SeqS, Fast Aneuploidy Screening Test-Sequencing System, to include applications in noninvasive prenatal testing (NIPT) and related know-how. In December, the company announced an exclusive license to the technology for preimplantation genetic screening (or PGS). FAST-SeqS is a simple, efficient method to detect non-invasively the chromosome number of a fetus by sequencing fetal DNA isolated from maternal plasma. The technology uses a single primer pair to selectively amplify distinct sections of the genome that occur on every chromosome. Compared to other maternal plasma DNA sequencing approaches, FAST-SeqS offers the powerful combination of simplicity in approach and lower cost critical elements for competitive advantage in this space.

Rockefeller, Johns Hopkins Behind Horrific Human Syphilis Experiments, Allege Guatemalan Victims in Lawsuit

Over 750 victims have sued The Rockefeller Foundation, the Johns Hopkins Hospital, the Johns Hopkins University, The Johns Hopkins University School of Medicine, the Johns Hopkins Bloomberg School of Public Health, and the Johns Hopkins Health System Corporation, alleging that they were the driving force behind human experiments in which vulnerable populations of Guatemalans were deceived and intentionally exposed to syphilis, gonorrhea and other venereal diseases and pathogens, without giving any informed consent. The experiments targeted school children, orphans, psychiatric hospital patients, prison inmates and military conscripts. The Obama Administration apologized to Guatemala for the Guatemala Experiments in 2010. The Administration tasked the Presidential Commission for the Study of Bioethical Issues to investigate the experiments. The details of the experiments were deliberately hidden from the world, and remained so until the Commission published its report in September 2011, confirming that barbaric human experiments constituting human rights violations occurred, for example: prostitutes were infected with venereal disease and then provided for sex to subjects for intentional transmission of the disease; subjects were inoculated by injection of syphilis spirochetes into the spinal fluid that bathes the brain and spinal cord, under the skin, and on mucous membranes; an emulsion containing syphilis or gonorrhea was spread under the foreskin of the penis in male subjects; the penis of male subjects was scraped or scarified and then coated with the emulsion containing syphilis or gonorrhea; a woman from the psychiatric hospital was injected with syphilis, developed skin lesions and wasting, and then had gonorrheal pus from a male subject injected into both of her eyes. Many of the Guatemalans developed venereal disease. Most were never treated. Researchers subjected the Guatemalans to repeated blood draws, lumbar punctures and cisternal punctures of the suboccipital portion of the brain, gynecological examinations, touching and penetration of sexual organs, and forced or coerced sexual contact. Key Rockefeller and Johns Hopkins researchers involved in the Guatemala Experiments, were also behind the now infamous Tuskegee experiments, in which 600 impoverished African-American sharecroppers were never informed they had syphilis, and were given placebos rather than real medicine. The researchers watched while the experiment subjects wasted away and infected their wives and children with the disease. The Tuskegee experiments were halted after being exposed by a whistleblower. The Guatemala victims have also sued Bristol-Myers Squibb, which supplied penicillin necessary for the Guatemala Experiments. The case has been filed in the Circuit Court in Baltimore City, Maryland. The victims are represented by three law firms: Meridian 361 International Law Group, PLLC of Portland, Maine; Escritorio Juridico Rodriguez Fajardo y Asociados of Caracas, Republica Bolivariana de Venezuela; and Salsbury, Clements, Bekman, Marder & Adkins of Baltimore, Maryland.

Similar Private Companies By Industry

Company Name Region
Destination Planning Corporation United States
First Wireless Group, Inc. United States
SCI Funeral & Cemetery Purchasing Cooperative, Inc. United States
Nottage and Ward, LLP United States
Hairart International, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Johns Hopkins University, please visit www.jhu.edu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.